Conditions: Parkinson's Disease Psychosis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 199
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the safety and efficacy of 40 mg pimavanserin compared to placebo in patients with Parkinson's disease psychosis (PDP).

Detailed description:

Arms:
arm 1: pimavanserin tartrate, 40 mg, tablet, once daily by mouth for 6 weeks arm 2: placebo, tablet, once daily by mouth for 6 weeks

Interventions: intervention 1: pimavanserin tartrate intervention 2: placebo
Intervention descriptions: intervention 1: pimavanserin tartrate, 40 mg, tablet, once daily by mouth for 6 weeks intervention 2: placebo, tablet, once daily by mouth for 6 weeks

Protocol document: